beta-farnesene: structure given in first source
ID Source | ID |
---|---|
PubMed CID | 5317319 |
CHEBI ID | 39242 |
MeSH ID | M0173355 |
Synonym |
---|
1,6,10-dodecatriene, 7,11-dimethyl-3-methylene-, (z)- |
(z)-.beta.-farnesene |
beta-farnesene |
(6z)-7,11-dimethyl-3-methylenedodeca-1,6,10-triene |
(6z)-7,11-dimethyl-3-methylene-1,6,10-dodecatriene |
beta-cis-farnesene |
cis-beta-farnesene |
28973-97-9 |
beta-(z)-farnesene |
CHEBI:39242 |
(6z)-7,11-dimethyl-3-methylidenedodeca-1,6,10-triene |
7,11-dimethyl-3-methylene-1,6,10-dodecatriene |
(z)-7,11-dimethyl-3-methylene-1,6,10-dodecatriene |
1,6,10-dodecatriene, 7,11-dimethyl-3-methylene-, (6z)- |
beta-farnesene, (6z)- |
g7f9bvf1ur , |
fema no. 3839, (6z)-beta- |
unii-g7f9bvf1ur |
.beta.-cis-farnesene |
.beta.-farnesene, (6z)- |
cis-.beta.-farnesene |
fema no. 3839, (6z)-.beta.- |
JSNRRGGBADWTMC-QINSGFPZSA-N |
b-farnesene |
Q27119785 |
(6z)-beta-farnesene |
DTXSID101017764 , |
dtxcid801475947 |
Class | Description |
---|---|
beta-farnesene | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 7 (5.65) | 18.2507 |
2000's | 23 (18.55) | 29.6817 |
2010's | 71 (57.26) | 24.3611 |
2020's | 23 (18.55) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 6 (4.80%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 119 (95.20%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Article | Year |
---|---|
Neuroprotective effects of farnesene against hydrogen peroxide-induced neurotoxicity in vitro. Cellular and molecular neurobiology, Volume: 34, Issue: 1 | 2014 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Article | Year |
---|---|
Engineering the oleaginous yeast Yarrowia lipolytica for β-farnesene overproduction. Biotechnology journal, Volume: 16, Issue: 7 | 2021 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |